A review argues that peripherally restricted CB1 inverse agonists and neutral CB1 antagonists can provide the metabolic benefits of CB1 blockade (reduced obesity and improved insulin sensitivity) without the psychiatric side effects that doomed rimonabant.
Read this if you are interested in how the lessons from rimonabant's failure are being applied to develop safer anti-obesity and diabetes drugs.
Peripheral CB1 blockade provides metabolic benefits without entering the brain
What the researchers found
The endocannabinoid system's overactivation in visceral obesity drives metabolic dysfunction through CB1 receptors. Rimonabant's clinical success in reducing weight and metabolic risk factors proved that CB1 blockade works, but its psychiatric side effects ended its use.
This review examines two promising alternatives. Peripherally restricted CB1 inverse agonists cannot cross the blood-brain barrier, so they target CB1 receptors only in metabolically active tissues (fat, liver, muscle) without affecting the brain. Preclinical studies show these compounds provide similar metabolic benefits without psychiatric effects.
Neutral CB1 antagonists block the receptor without reducing its baseline signaling (unlike inverse agonists). This property may further reduce the risk of mood-related side effects.
Additionally, CB1 blockade may reduce endoplasmic reticulum and mitochondrial stress, which are contributors to obesity-induced insulin resistance, adding another mechanism for metabolic benefit.
Why it matters
Obesity and type 2 diabetes are among the largest global health challenges. CB1 blockade has proven metabolic efficacy, and this review provides a roadmap for how to achieve those benefits safely. The peripheral restriction strategy could rehabilitate an entire drug class.
The numbers in context
Rimonabant reduced food intake, abdominal fat, fasting glucose, and cardiometabolic risk factors in humans. Peripherally restricted CB1 inverse agonists showed similar effects in preclinical models without psychiatric side effects. Neutral antagonists also effective in animal models.
How the study worked
Narrative review of preclinical evidence for peripherally restricted CB1 inverse agonists and neutral CB1 antagonists in obesity and type 2 diabetes treatment.
What this study cannot tell us
Most evidence is preclinical. No peripherally restricted or neutral CB1 antagonists have completed large-scale human trials. The assumption that peripheral restriction eliminates psychiatric effects needs clinical validation. Long-term safety data are lacking.
How to read the evidence
Narrative review synthesizing preclinical evidence for a promising therapeutic strategy, but without clinical trial data.
When this study was published
Published in 2016. Several peripheral CB1 antagonist candidates have advanced in development since.
The bigger picture
The rimonabant story is one of the most prominent drug development failures in recent history. The emergence of peripherally restricted and neutral antagonist approaches suggests the field has learned from this failure and may eventually deliver safe, effective CB1-targeting metabolic drugs.
Questions still open
- Will peripherally restricted CB1 antagonists succeed in human trials? Is there a role for low-dose centrally acting CB1 antagonists? Could these drugs treat both obesity and type 2 diabetes simultaneously?
Common questions
Can CB1 blockers treat obesity safely?
How might these drugs work for diabetes?
Read the original research
Controlled downregulation of the cannabinoid CB1 receptor provides a promising approach for the treatment of obesity and obesity-derived type 2 diabetes.
Cell stress & chaperones, 21(1), 1-7
Citation
Lu, Dai; Dopart, Rachel; Kendall, Debra A. (2016). Controlled downregulation of the cannabinoid CB1 receptor provides a promising approach for the treatment of obesity and obesity-derived type 2 diabetes.. Cell stress & chaperones, 21(1), 1-7. https://doi.org/10.1007/s12192-015-0653-5
Explore the wider topic
- How THC Affects Your Amygdala: The Brain's Threat Detector and Cannabis
- The Anandamide Connection: Your Body's Natural Bliss Molecule
- How Long for Cannabinoid Receptors to Return to Normal
- Cannabis and the Developing Brain: What Every Teenager (and Parent) Should Know
- Why Can't I Enjoy Anything Without Weed? The Science Behind It
- Dopamine Recovery After Quitting Weed: What the Science Says
- The Endocannabinoid System Explained Simply: What It Does and Why It Matters
- Your Endocannabinoid System Explained: Why Withdrawal Happens
- Your Nervous System After Quitting Weed: Fight or Flight
- Using Weed Under 18: What It Does to Your Developing Brain
- What THC Does to Your Brain: Why Withdrawal Happens
- THC and Your Prefrontal Cortex: What Cannabis Does to Your Decision-Making Brain
- Weed, Cortisol, and Stress: What Cannabis Does to Your Stress Hormones
- Weed and Memory: What the Science Says About THC and Your Hippocampus
- Weed and Motivation: Is Amotivational Syndrome Real?
- Weed and Your Nervous System: What THC Actually Does to Your Brain and Body
- How Weed Rewires Your Reward System (And How to Reset It)